Huntington's Patients Finally Get Real Hope

uniQure's AMT-130 slowed Huntington's progression 75% in a Phase I/II trial, a milestone for a once-untreatable disease

1 Jul 2026

uniQure said on Thursday that its experimental gene therapy, AMT-130, met the main goal of a Phase I/II trial, slowing the progression of Huntington's disease by 75 per cent at the highest dose tested. The Dutch biotechnology company's shares are likely to draw fresh scrutiny from investors tracking the gene-therapy sector, where clinical setbacks have been more common than breakthroughs.

Patients on the high dose showed improvements across several measures, including disease biomarkers, daily function and a composite score used to track Huntington's severity. No approved treatment currently slows the disease itself; existing drugs only ease symptoms. Huntington's is an inherited, fatal neurological disorder that affects thousands of families in the US alone, and for which no disease-modifying therapy has reached the market.

Sarah Tabrizi, a neurologist at University College London who led the trial, called the results "an immensely exciting development for the Huntington's field." Her assessment reflects growing confidence in gene-silencing, a technique that switches off the faulty gene responsible for the disease, as a workable treatment approach rather than a theoretical one.

Regulators have already signalled interest in the programme. The US Food and Drug Administration granted AMT-130 both Breakthrough Therapy and Regenerative Medicine Advanced Therapy status, designations meant to speed up review for treatments addressing serious unmet medical need. Company representatives met with the FDA in March, and uniQure is now targeting an early submission of its Biologics License Application, the formal request for US marketing approval.

The implications reach beyond one company's pipeline. A successful filing would test whether gene-silencing platforms can move from experimental promise to regulatory approval, a transition that has stalled or failed for several rival programmes in neurodegenerative disease. Contract manufacturers and specialty pharmacy networks, both of which handle the complex logistics of gene therapies, are watching the filing timeline closely. So too are investors weighing whether other companies pursuing similar mechanisms might benefit from a favourable precedent.

Whether the FDA ultimately approves AMT-130 remains an open question, and one that will shape how quickly gene-silencing therapies reach patients with other neurodegenerative conditions.